Abstract
Twenty-two patients with small-cell carcinoma of the lung who had failed combination chemotherapy were treated with VP-16-213 as a single agent. A partial remission was achieved in one patient. Twenty-three percent of the patients experienced arrest of disease for a median of 31 weeks. Leukopenia was a major complicating side effect.
Original language | English (US) |
---|---|
Pages (from-to) | 155-157 |
Number of pages | 3 |
Journal | Cancer Clinical Trials |
Volume | 4 |
Issue number | 2 |
State | Published - 1981 |
ASJC Scopus subject areas
- Medicine(all)